These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26084627)
1. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children. Maximova N; Zanon D; Rovere F; Maestro A; Schillani G; Paparazzo R Int J Hematol; 2015 Nov; 102(5):626-32. PubMed ID: 26084627 [TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A; Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. Hartranft ME; Clemmons AB; DeRemer DL; Kota V J Oncol Pharm Pract; 2017 Jan; 23(1):10-17. PubMed ID: 26471738 [TBL] [Abstract][Full Text] [Related]
4. Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series. Lancman G; Coltoff A; Steinberg A Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):171-174. PubMed ID: 30030975 [TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children. Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752 [TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation. Battipaglia G; Ruggeri A; Brissot E; Mamez AC; Malard F; Belhocine R; Vekhoff A; Giannotti F; Ledraa T; Labopin M; Rubio MT; Mohty M Bone Marrow Transplant; 2015 Dec; 50(12):1574-7. PubMed ID: 26281029 [No Abstract] [Full Text] [Related]
7. Romiplostim for the management of perioperative thrombocytopenia. Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837 [TBL] [Abstract][Full Text] [Related]
8. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Calmettes C; Vigouroux S; Tabrizi R; Milpied N Bone Marrow Transplant; 2011 Dec; 46(12):1587-9. PubMed ID: 21927039 [No Abstract] [Full Text] [Related]
9. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. Moussa MM; Mowafy N J Gastroenterol Hepatol; 2013 Feb; 28(2):335-41. PubMed ID: 22849409 [TBL] [Abstract][Full Text] [Related]
10. Romiplostim in the management of the thrombocytopenic surgical patient. Marshall AL; Goodarzi K; Kuter DJ Transfusion; 2015 Oct; 55(10):2505-10. PubMed ID: 26033367 [TBL] [Abstract][Full Text] [Related]
11. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500 [TBL] [Abstract][Full Text] [Related]
13. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. DasGupta RK; Levine L; Wiczer T; Cataland S J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625 [TBL] [Abstract][Full Text] [Related]
14. Romiplostim for management of chemotherapy-induced thrombocytopenia. Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994 [TBL] [Abstract][Full Text] [Related]
15. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Mahat U; Rotz SJ; Hanna R Biol Blood Marrow Transplant; 2020 Mar; 26(3):e65-e73. PubMed ID: 31830528 [TBL] [Abstract][Full Text] [Related]
16. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia. Park S; Yoon SS; Lee JH; Park JS; Jang JH; Lee JW Int J Hematol; 2016 Jan; 103(1):44-52. PubMed ID: 26511480 [TBL] [Abstract][Full Text] [Related]
17. Romiplostim or standard of care in patients with immune thrombocytopenia. Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381 [TBL] [Abstract][Full Text] [Related]
18. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437 [TBL] [Abstract][Full Text] [Related]